1. Home
  2. EVAX vs CNSP Comparison

EVAX vs CNSP Comparison

Compare EVAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • CNSP
  • Stock Information
  • Founded
  • EVAX 2008
  • CNSP 2017
  • Country
  • EVAX Denmark
  • CNSP United States
  • Employees
  • EVAX N/A
  • CNSP N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • CNSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • CNSP Health Care
  • Exchange
  • EVAX Nasdaq
  • CNSP Nasdaq
  • Market Cap
  • EVAX 8.7M
  • CNSP 6.5M
  • IPO Year
  • EVAX 2021
  • CNSP 2019
  • Fundamental
  • Price
  • EVAX $2.49
  • CNSP $0.14
  • Analyst Decision
  • EVAX Strong Buy
  • CNSP Strong Buy
  • Analyst Count
  • EVAX 3
  • CNSP 1
  • Target Price
  • EVAX $33.33
  • CNSP $0.50
  • AVG Volume (30 Days)
  • EVAX 6.9M
  • CNSP 38.3M
  • Earning Date
  • EVAX 03-26-2025
  • CNSP 03-31-2025
  • Dividend Yield
  • EVAX N/A
  • CNSP N/A
  • EPS Growth
  • EVAX N/A
  • CNSP N/A
  • EPS
  • EVAX N/A
  • CNSP N/A
  • Revenue
  • EVAX $3,295,000.00
  • CNSP N/A
  • Revenue This Year
  • EVAX $9,039.73
  • CNSP N/A
  • Revenue Next Year
  • EVAX $1.47
  • CNSP N/A
  • P/E Ratio
  • EVAX N/A
  • CNSP N/A
  • Revenue Growth
  • EVAX N/A
  • CNSP N/A
  • 52 Week Low
  • EVAX $2.22
  • CNSP $0.08
  • 52 Week High
  • EVAX $22.50
  • CNSP $23.90
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 39.85
  • CNSP 70.62
  • Support Level
  • EVAX $2.30
  • CNSP $0.09
  • Resistance Level
  • EVAX $2.80
  • CNSP $0.12
  • Average True Range (ATR)
  • EVAX 0.51
  • CNSP 0.02
  • MACD
  • EVAX 0.03
  • CNSP 0.00
  • Stochastic Oscillator
  • EVAX 6.97
  • CNSP 52.83

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Share on Social Networks: